{"DataElement":{"publicId":"2186009","version":"1","preferredName":"Prior Cancer Treatment Ind-2","preferredDefinition":"the yes/no indicator that asks whether prior cancer treatment was received.","longName":"PRIOR_CA_TX_IND2","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2010136","version":"2.31","preferredName":"Prior Cancer Treatment","preferredDefinition":"information related to the prior administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process of a tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.","longName":"PRI_CA_TX","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206692","version":"1","preferredName":"Prior Malignant Neoplasm","preferredDefinition":"Earlier in time or order.:A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004","longName":"C25629:C9305","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-003B-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2554155","version":"1","preferredName":"Therapeutic Procedure","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"249AD8D2-9892-0146-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-12-14","endDate":null,"createdBy":"UMLLOADER_TUMOR","dateCreated":"2006-12-14","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99BA9DC8-4992-4E69-E034-080020C9C0E0","latestVersionIndicator":"Yes","beginDate":"2008-03-31","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811871","version":"1","longName":"Colorectal","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811954","version":"1","longName":"Eligibility Criteria","context":"CTEP"}]},{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"3021954","version":"1","longName":"Caris Life Sciences","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3060675","version":"1","longName":"Biospecimen Repository","context":"NCIP"},{"publicId":"10000190","version":"1","longName":"Colorectal","context":"NCIP"}]},{"publicId":"3314482","version":"1","longName":"Type of Category","context":"ECOG-ACRIN","ClassificationSchemeItems":[{"publicId":"10000277","version":"1","longName":"Eligibility","context":"ECOG-ACRIN"}]},{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4104903","version":"1","longName":"GOG-0170R","context":"NRG"},{"publicId":"10000427","version":"1","longName":"GOG-0170R","context":"NRG"},{"publicId":"10000426","version":"1","longName":"GOG-0170R","context":"NRG"},{"publicId":"4104897","version":"1","longName":"GOG-0250","context":"NRG"},{"publicId":"10000501","version":"1","longName":"GOG-0170Q","context":"NRG"},{"publicId":"4104902","version":"1","longName":"GOG-0170Q","context":"NRG"},{"publicId":"10000502","version":"1","longName":"GOG-0170Q","context":"NRG"},{"publicId":"10000346","version":"1","longName":"GOG-0186K","context":"NRG"},{"publicId":"10000345","version":"1","longName":"GOG-0186K","context":"NRG"},{"publicId":"4104907","version":"1","longName":"GOG-0186K","context":"NRG"},{"publicId":"4104891","version":"1","longName":"GOG-0229N","context":"NRG"},{"publicId":"4104882","version":"1","longName":"GOG-0237","context":"NRG"},{"publicId":"4171057","version":"1","longName":"RTOG-0937","context":"NRG"},{"publicId":"10000276","version":"1","longName":"GOG-0283","context":"NRG"},{"publicId":"4104930","version":"1","longName":"GOG-0283","context":"NRG"},{"publicId":"10000275","version":"1","longName":"GOG-0283","context":"NRG"},{"publicId":"4104941","version":"1","longName":"GOG-0281","context":"NRG"},{"publicId":"10000705","version":"1","longName":"GOG-0281","context":"NRG"},{"publicId":"4104900","version":"1","longName":"GOG-0277","context":"NRG"},{"publicId":"4104892","version":"1","longName":"GOG-0229O","context":"NRG"},{"publicId":"4104885","version":"1","longName":"GOG-0263","context":"NRG"},{"publicId":"4104901","version":"1","longName":"GOG-0286B","context":"NRG"}]}],"AlternateNames":[{"name":"caBIG","type":"USED_BY","context":"NCIP"},{"name":"PRIOR_CA_TX_IND2","type":"USED_BY","context":"CTEP"},{"name":"SWOG","type":"USED_BY","context":"SWOG"},{"name":"CDUSRT","type":"OID, SWOG","context":"SWOG"},{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"PRIOR_CA_TX_IND2","type":"USED_BY","context":"Alliance"},{"name":"PRIOR_CA_TX_IND2","type":"USED_BY","context":"NRG"},{"name":"ECOG-ACRIN","type":"USED_BY","context":"ECOG-ACRIN"},{"name":"PRIOR_CA_TX_IND2","type":"USED_BY","context":"CITN"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"CITN","type":"USED_BY","context":"CITN"},{"name":"PR_CHX_ADM_IND","type":"COG Form Element","context":"COG"}],"ReferenceDocuments":[{"name":"Prior chemotherapy or radiati","type":"Preferred Question Text","description":"Prior chemotherapy or radiation therapy for treatment of this malignancy","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Patient has received prior treatment for breast cancer, including radiation, endocrine therapy, chemotherapy or investigational agent. Patients whose diagnosis was established by incisional biopsy are not eligible","url":null,"context":"CTEP"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Has the patient received prior treatment for newly diagnosed AML","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Prior systemic chemotherapy or radiation therapy","url":null,"context":"CTEP"},{"name":"CRF Text4","type":"Alternate Question Text","description":"Prior treatment for invasive breast cancer, including radiation, endocrine therapy, chemotherapy or investigational agent","url":null,"context":"CTEP"},{"name":"CRF Text3","type":"Alternate Question Text","description":"No prior chest or upper abdomen radiotherapy; prior therapy with cisplatin, docetaxel, panitumumab or other anti-EGFR therapy; or prior esophageal or gastric surgery","url":null,"context":"CTEP"},{"name":"Has patient had ANY prior cancer treatment?","type":"Alternate Question Text","description":"Has patient had ANY prior cancer treatment?","url":null,"context":"NCIP"},{"name":"CRF Text5","type":"Alternate Question Text","description":"Prior chemotherapy, radiation therapy, immunotherapy, or biologic therapy for recurrent or metastatic colorectal cancer","url":null,"context":"CTEP"},{"name":"CRF Text8","type":"Alternate Question Text","description":"Has the patient received prior chemotherapy/radiation therapy treatment?","url":null,"context":"CTEP"},{"name":"CRF Text10","type":"Alternate Question Text","description":"Has the patient had a prior malignancy and been treated with systemic chemotherapy or radiation therapy","url":null,"context":"CTEP"},{"name":"Caris Alternate Question","type":"Alternate Question Text","description":"Previous Treatment for Cancer","url":null,"context":"CTEP"},{"name":"CRF Text11","type":"Alternate Question Text","description":"Has the patient ever been treated with radiation therapy or chemotherapy for vaginal or cervical cancer?","url":null,"context":"CTEP"},{"name":"CRF Text7","type":"Alternate Question Text","description":"Treatment Received","url":null,"context":"CTEP"},{"name":"CRF Text9","type":"Alternate Question Text","description":"Has the patient had prior therapy with dalantercept or other inhibitor of the ALK1 pathway?","url":null,"context":"CTEP"},{"name":"COG_CRF_TEXT_1","type":"Alternate Question Text","description":"Was patient treated with radiation alone or less than 4 cycles of chemotherapy","url":null,"context":"CTEP"},{"name":"CRF Text6","type":"Alternate Question Text","description":"Prior chemotherapy, small molecule cell cycle inhibitors, or other investigational agents","url":null,"context":"CTEP"},{"name":"CRF Text12","type":"Alternate Question Text","description":"Has the patient had prior therapy with docetaxel or gemcitabine or doxorubicin?","url":null,"context":"CTEP"},{"name":"CRF Text13","type":"Alternate Question Text","description":"Has the patient had previous treatment with dalantercept or any other anti-ALK1 (activin receptor-like kinase 1) agent?","url":null,"context":"CTEP"},{"name":"CRF Text 15","type":"Alternate Question Text","description":"Did the patient have any prior breast or thoracic radiation therapy for any condition?","url":null,"context":"CTEP"},{"name":"CRF Text14","type":"Alternate Question Text","description":"Has the patient had previous treatment with cabozantinib?","url":null,"context":"CTEP"},{"name":"CRF Text17","type":"Alternate Question Text","description":"Has the patient had prior therapy with trametinib or any other MEK inhibitor?","url":null,"context":"CTEP"},{"name":"CRf Text19","type":"Alternate Question Text","description":"Has the patient received prior MEK, KRAS, or BRAF inhibitor therapy?","url":null,"context":"CTEP"},{"name":"CRF Text15","type":"Alternate Question Text","description":"Has the patient had prior therapy with EGEN-001?","url":null,"context":"CTEP"},{"name":"CRF Text20","type":"Alternate Question Text","description":"Has the patient received prior chemotherapy or targeted therapy, including chemotherapy used for radiation sensitization for treatment of endometrial cancer?","url":null,"context":"CTEP"},{"name":"CRF Text16","type":"Alternate Question Text","description":"Has the patient had prior treatment with docetaxel or gemcitabine or bevacizumab?","url":null,"context":"CTEP"},{"name":"CRF Text18","type":"Alternate Question Text","description":"Prior treatment with MEK inhibitor","url":null,"context":"CTEP"},{"name":"CRF Text 21","type":"Alternate Question Text","description":"Did the patient receive prior thoracic radiation therapy","url":null,"context":"CTEP"},{"name":"Radiation therapy?","type":"Alternate Question Text","description":"Radiation therapy?","url":null,"context":"SWOG"},{"name":"NRG_CRF Text","type":"Alternate Question Text","description":"Has the patient had prior treatment with dasatinib, imatinib or nilotinib?","url":null,"context":"NRG"},{"name":"NRG_CRF Text 2","type":"Alternate Question Text","description":"Has the patient received prior treatment with EGEN-001?","url":null,"context":"NRG"},{"name":"COG_CRF_TEXT_2","type":"Alternate Question Text","description":"Was patient previously treated for a non-NRSTS cancer?","url":null,"context":"CTEP"},{"name":"NRG_CRF Text 3","type":"Alternate Question Text","description":"Has the patient received previous therapy with a MET inhibitor?","url":null,"context":"NRG"},{"name":"COG CRF TEXT 3","type":"Alternate Question Text","description":"Has the patient received prior radiotherapy or chemotherapy with the exception of  dexamethasone?","url":null,"context":"CTEP"},{"name":"COG CRF Text 6","type":"Alternate Question Text","description":"Did patient previously receive denosumab?","url":null,"context":"COG"},{"name":"EAI142 Text","type":"Alternate Question Text","description":"Prior endocrine therapy for metastatic disease (i.e., must be first-line endocrine therapy for metastatic disease)","url":null,"context":"ECOG-ACRIN"},{"name":"ACRIN 1","type":"Alternate Question Text","description":"Has the participant received prior chemotherapy or radiation therapy for lung cancer?","url":null,"context":"ECOG-ACRIN"},{"name":"Has patient received treatment for Stage IV disease?","type":"Alternate Question Text","description":"Has patient received treatment for Stage IV disease?","url":null,"context":"SWOG"},{"name":"COG CRF Text 5","type":"Alternate Question Text","description":"Did patient receive prior therapy standard to tumor type?","url":null,"context":"CTEP"},{"name":"COG CRF Text 4","type":"Alternate Question Text","description":"Has patient received previous treatment with IMGN901?","url":null,"context":"CTEP"},{"name":"CITN 1","type":"Alternate Question Text","description":"Prior therapy such as chemotherapy or radiation therapy or anti-tumor experimental therapy for pancreatic cancer","url":null,"context":"CITN"},{"name":"COG_CRF_TEXT 5","type":"Alternate Question Text","description":"Does patient have use of select CYP2D6 inhibitor or inducer medications?","url":null,"context":"CTEP"},{"name":"COG CRF Text 7","type":"Alternate Question Text","description":"Is patient currently using select CYP2D6 inhibitor or inducer medications?","url":null,"context":"COG"},{"name":"NRG_CRF Text 4","type":"Alternate Question Text","description":"Did the patient receive at least 4 cycles of first-line/induction chemotherapy?","url":null,"context":"NRG"},{"name":"CRF Text21","type":"Alternate Question Text","description":"Prior chemotherapy or chemoradiation for pancreatic cancer?","url":null,"context":"Alliance"},{"name":"NRG_CRF Text 5","type":"Alternate Question Text","description":"Did the patient receive at least 4 cycles of first-line/induction systemic therapy?","url":null,"context":"NRG"},{"name":"COG CRF Text 8","type":"Alternate Question Text","description":"Has patient received previous treatment with XL184 or another MET/HGF inhibitor?","url":null,"context":"COG"},{"name":"COG CRF Text 9","type":"Alternate Question Text","description":"Has patient received prior treatment with  dasatinib, or any other BCR-ABL1 inhibitor other than Imatinib?","url":null,"context":"COG"},{"name":"CRF Text 22","type":"Alternate Question Text","description":"Has the patient had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study entry?","url":null,"context":"CTEP"},{"name":"NRG_CRF Text 6","type":"Alternate Question Text","description":"Prior chemotherapy or radiotherapy for any brain tumor","url":null,"context":"NRG"},{"name":"CRF Text 23","type":"Alternate Question Text","description":"Has the patient had chemotherapy or radiation within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study?","url":null,"context":"CTEP"},{"name":"CRF Text24","type":"Alternate Question Text","description":"has the patient had prior medical therapy or radiation therapy for MM?","url":null,"context":"Alliance"},{"name":"NRG_CRF_TEXT 7","type":"Alternate Question Text","description":"Did the patient receive 4 cycles of first-line/induction systemic therapy compromising of immunotherapy and/or platinum based chemotherapy?","url":null,"context":"NRG"},{"name":"CRF Text 25","type":"Alternate Question Text","description":"Has the patient had prior chemotherapy, endocrine therapy, radiotherapy, or investigational agents within 4 weeks?","url":null,"context":"CTEP"},{"name":"COG_CRF_TEXT_10","type":"Alternate Question Text","description":"Is patient receiving indicated CYP2D6 and CYP1A2 agents","url":null,"context":"COG"},{"name":"NRG_CRF_Text 8","type":"Alternate Question Text","description":"Has the patient had prior chemotherapy or systemic therapy for the study cancer?","url":null,"context":"NRG"},{"name":"CRF_Text 24","type":"Alternate Question Text","description":"Histologically proven diagnosis of adenocarcinoma or squamous cell carcinoma of the thoracic esophagus or gastroesophageal junction(Siewert I-II)?","url":null,"context":"NRG"},{"name":"CRF_Text20","type":"Alternate Question Text","description":"Induction chemotherapy for this cancer?","url":null,"context":"NRG"},{"name":"CRF Text26","type":"Alternate Question Text","description":"Is the patient currently receiving treatment for this cancer?","url":null,"context":"Alliance"},{"name":"COG CRF Text 11","type":"Alternate Question Text","description":"Has patient received any prior tumor-directed therapy including chemotherapy, radiation therapy, immunotherapy, or bone marrow transplant, other than surgical intervention?","url":null,"context":"COG"},{"name":"NRG_CRF_Text 9","type":"Alternate Question Text","description":"Has the patient had more than 1 cycle of prior platinum-based chemotherapy for SCLC prior to enrollment?","url":null,"context":"NRG"},{"name":"CRF Text 27","type":"Alternate Question Text","description":"One prior cycle of R-chemo","url":null,"context":"Alliance"},{"name":"CRF Text30","type":"Alternate Question Text","description":"Receipt of anti-cancer therapy?","url":null,"context":"Alliance"},{"name":"COG_CRF_TEXT_12","type":"Alternate Question Text","description":"Has the patient received any prior therapy except for surgery and steroid medications?","url":null,"context":"COG"},{"name":"CRF Text29","type":"Alternate Question Text","description":"Prior adjuvant or neoadjuvant chemotherapy or chemoradiation?","url":null,"context":"Alliance"},{"name":"CRF_text_30","type":"Alternate Question Text","description":"Prior systemic chemotherapy for the study cancer?","url":null,"context":"NRG"},{"name":"CRF Text_29","type":"Alternate Question Text","description":"Has the patient received any chemotherapy, targeted therapy, immunotherapy or investigational medication within 4 weeks prior to study entry?","url":null,"context":"NRG"},{"name":"EAI142_2","type":"Alternate Question Text","description":"Has the patient had  prior endocrine therapy for metastatic disease (i.e. other first-line endocrine therapy for metastatic disease)?","url":null,"context":"ECOG-ACRIN"},{"name":"CRF Text 28","type":"Alternate Question Text","description":"Has the patient received 1 cycle of R-chemotherapy prior to registration/randomization?","url":null,"context":"Alliance"},{"name":"COG CRF TEXT 12","type":"Alternate Question Text","description":"Did patient receive any prior anti cancer therapy?","url":null,"context":"COG"},{"name":"CRF Text31","type":"Alternate Question Text","description":"Prior treatment with temozolomide, dacarbazine, or a poly ADP ribose polymerase (PARP) inhibitor?","url":null,"context":"Alliance"},{"name":"NRG CRF_Text10","type":"Alternate Question Text","description":"Does the patient have a history of prior cancer and received chemotherapy within the past 12 months, hormonal therapy within the past 90 days or radiotherapy to the abdomen or pelvis at any prior time?","url":null,"context":"NRG"},{"name":"CRF Text32","type":"Alternate Question Text","description":"Prior Treatment with Temozolomide, Dacarbazine, or a Poly ADP Ribose Polymerase (PARP) Inhibitor","url":null,"context":"Alliance"},{"name":"COG CRF Text 13","type":"Alternate Question Text","description":"Has the patient received any prior therapy other than surgery and/or steroid medications?","url":null,"context":"COG"},{"name":"COG CRF Text 12","type":"Alternate Question Text","description":"Has the patient received any therapy with vinblastine within 6 months prior to enrollment?","url":null,"context":"COG"},{"name":"COG CRF Text 14","type":"Alternate Question Text","description":"Has the patient received any therapy with vinblastine within 6 months prior to enrollment?","url":null,"context":"COG"},{"name":"NRG_CRF Text 16","type":"Alternate Question Text","description":"Has the patient received FOLFOX  induction chemotherapy for the current malignancy with the last dose no more than 90 days and no less than 10 days prior to step 1 registration?","url":null,"context":"NRG"},{"name":"CRF Text33","type":"Alternate Question Text","description":"Has the patient received prior therapy?","url":null,"context":"Alliance"},{"name":"NRG_CRF_Text 11","type":"Alternate Question Text","description":"Did the patient receive 4 or 5 cycles of first-line/induction systemic therapy compromising of immunotherapy and/or platinum based chemotherapy?","url":null,"context":"NRG"},{"name":"COG CRF Text 20","type":"Alternate Question Text","description":"Has the patient received any prior therapy for his/her CNS malignancy, other than surgery and steroid medications?","url":null,"context":"COG"},{"name":"ARST2031 SMN exclusion","type":"Alternate Question Text","description":"Does the patient have RMS that is considered a second malignancy or previous cancer(s) that were treated with chemotherapy and/or radiation?  Surgical resection alone of previous cancer(s) is allowed.","url":null,"context":"COG"},{"name":"NRG_eCRF_Text","type":"Alternate Question Text","description":"Has the patient received prior chemotherapy, biologic therapy, or targeted therapy for treatment of endometrial carcinoma?","url":null,"context":"NRG"},{"name":"CRF Text34","type":"Alternate Question Text","description":"Prior chemotherapy or immunotherapy for advanced NSCLC?","url":null,"context":"Alliance"},{"name":"NRG_CRF_Text_12","type":"Alternate Question Text","description":"Has the patient received prior chemotherapy or radiotherapy within 4 weeks of registration?","url":null,"context":"NRG"},{"name":"CC08 CRF Text 1","type":"Alternate Question Text","description":"Does the patient have a history of prior cancer and received chemotherapy within the past 12 months, or radiotherapy to the abdomen or pelvis at any prior time?","url":null,"context":"NRG"},{"name":"NRG CC008 Text 1","type":"Alternate Question Text","description":"Does the patient have a history of any prior cancer who has received chemotherapy within past 30 days or radiotherapy to abdomen or pelvis at any prior time?","url":null,"context":"NRG"},{"name":"COG CRF Text 15","type":"Alternate Question Text","description":"Has the patient had any prior therapy to the study eye: focal, local or systemic chemotherapy or radiation therapy?","url":null,"context":"COG"},{"name":"NRG_CRF_Text_2","type":"Alternate Question Text","description":"Has the patient received chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to registration?","url":null,"context":"NRG"},{"name":"COG CRF Text 16","type":"Alternate Question Text","description":"Did patient receive Induction chemotherapy per the indicated criteria?","url":null,"context":"COG"},{"name":"COG CRF Text 17","type":"Alternate Question Text","description":"Has the patient been previously treated for cHL with chemotherapy, radiation, or antibody-based treatment?","url":null,"context":"COG"},{"name":"COG CRF Text 18","type":"Alternate Question Text","description":"Does the patient have administration of prior chemotherapy, radiation, or antibody-based treatment for cHL?","url":null,"context":"COG"},{"name":"CRF Text35","type":"Alternate Question Text","description":"Prior chemotherapy for advanced NSCLC?","url":null,"context":"Alliance"},{"name":"NRG CRF Text 1","type":"Alternate Question Text","description":"Has the patient had greater than or equal to 1 treatment regimen?","url":null,"context":"NRG"}],"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"DFE4C1DB-5304-3791-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-07-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-07-23","modifiedBy":"TSESU","dateModified":"2023-09-05","changeDescription":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":"6/14/2023: added AQT per cadsr0002525.wz","unresolvedIssues":null,"deletedIndicator":"No"}}